Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T15:36:37.270Z.
Calculation as of: 2026-10-06T15:36:37.270Z.
Quote observation: 2026-10-06T15:35:07.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 31946573a42b73cd13b381604bc2f467f5098c78190e00cee0d2639f3054c777
PE RATIO
N/A
Market Cap
$701.53M
PE Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| 4D Molecular Therapeutics, Inc. (FDMT) | $676.45M | N/A | N/A | N/A | N/A |
| MiMedx Group, Inc. (MDXG)vs › | $670.12M | 114.94 | 37.43 | 206.22 | 206.22 |
| Helus Pharma Inc. (HELP)vs › | $684.61M | N/A | N/A | N/A | N/A |
| Annexon, Inc. (ANNX)vs › | $691.42M | N/A | N/A | N/A | N/A |
| Anteris Technologies Global Corp. (AVR)vs › | $701.53M | N/A | N/A | N/A | N/A |
| OmniAb, Inc. (OABI)vs › | $645.85M | N/A | N/A | N/A | N/A |
| Aura Biosciences, Inc. (AURA)vs › | $645.84M | N/A | N/A | N/A | N/A |
| Climb Bio, Inc. (CLYM)vs › | $640.40M | N/A | N/A | N/A | N/A |
| Olema Pharmaceuticals, Inc. (OLMA)vs › | $713.63M | N/A | N/A | N/A | N/A |
| Collegium Pharmaceutical, Inc. (COLL)vs › | $722.58M | 17.97 | 23.33 | 39.10 | 32.90 |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$12.94
Forward EPS (Est.)
$-4.14
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
